Replacement of huntingtin exon 1 by trans-splicing

Cellular and Molecular Life Sciences

Volumn 69, Issue 24, 2012, Pages 4191-4204

  Rindt, Hansjörg ^a   Yen, Pei Fen ^a   Thebeau, Christina N ^b   Peterson, Troy S ^a   Weisman, Gary A ^a,b   Lorson, Christian L ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

Author keywords

Huntington's disease; Neurodegeneration; RNA based therapeutics; Spliceosome mediated trans splicing

Indexed keywords

HUNTINGTIN; MESSENGER RNA PRECURSOR;

ALLELE; ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; EXON; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUNTINGTIN GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RNA ANALYSIS; SPLICEOSOME; STRUCTURE ANALYSIS; TRANS SPLICING;

CELLS, CULTURED; EXONS; GENETIC THERAPY; HEK293 CELLS; HUMANS; LENTIVIRUS; NERVE TISSUE PROTEINS; RNA PRECURSORS; RNA, MESSENGER; SPLICEOSOMES; TRANS-SPLICING; TRANSFECTION;

EID: 84870680200     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-012-1083-5     Document Type: Article

References (70)

1. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577
2. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, Hayden MR (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811-823
3. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 11:155-163
4. Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM, Ge P, Vonsattel JP, Gusella JF, Joyner AL et al (1995) Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269:407-410
5. MacDonald ME (2003) Huntingtin: alive and well and working in middle management. Sci STKE 207:pe48
6. Li SH, Li XJ (2004)Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20:146-154
7. Ferrante RJ, Gutekunst CA, Persichetti F, McNeil SM, Kowall NW, Gusella JF, MacDonald ME, Beal MF, Hersch SM (1997) Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J Neurosci 17: 3052-3063
8. Fusco FR, Chen Q, Lamoreaux WJ, Figueredo-Cardenas G, Jiao Y, Coffman JA, Surmeier DJ, Honig MG, Carlock LR, Reiner A (1999) Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J Neurosci 19:1189-1202
9. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattel JP, Carraway R, Reeves SA et al (1995) Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14:1075-1081
10. Velier J, Kim M, Schwarz C, Kim TW, Sapp E, Chase K, Aronin N, DiFiglia M (1998) Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp Neurol 152:34-40
11. Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, Sapp E, Wang Y, Qin ZH, Chen JD, Nevins JR, Aronin N, DiFiglia M (2002) Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 277:7466-7476
12. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, Marder K, Penchaszadeh G, Roberts SA, Gayan J, Brocklebank D, Cherny SS, Cardon LR, Gray J, Dlouhy SR, Wiktorski S, Hodes ME, Conneally PM, Penney JB, Gusella J, Cha JH, Irizarry M, Rosas D, Hersch S, Hollingsworth Z, Mac-Donald M, Young AB, Andresen JM, Housman DE, De Young MM, Bonilla E, Stillings T, Negrette A, Snodgrass SR, Martinez-Jaurrieta MD, Ramos-Arroyo MA, Bickham J, Ramos JS, Marshall F, Shoulson I, Rey GJ, Feigin A, Arnheim N, Acevedo-Cruz A, Acosta L, Alvir J, Fischbeck K, Thompson LM, Young A, Dure L, O'Brien CJ, Paulsen J, Brickman A, Krch D, Peery S, Hogarth P, Higgins DS Jr, Landwehrmeyer B (2004)Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci USA 101:3498-3503
13. Walker FO (2007) Huntington's disease. Lancet 369:218-228
14. Cha JH (2000)Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23:387-392
15. Bates G, Benn C (2002) The polyglutamine diseases. In: Bates G, Harper P and Jones L (eds) Huntington's disease, Oxford University Press, London, p 429-474
16. Hickey MA, Chesselet MF (2003) Apoptosis in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 27:255-265
17. DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA (2004)Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol 33:517-533
18. Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, Hobbs NZ, Mandelli ML, Grisoli M, Bjorkhem I, Cattaneo E, Di Donato S (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131:2851-2859
19. Duennwald ML, Lindquist S (2008) Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev 22:3308-3319
20. Dragatsis I, Levine MS, Zeitlin S (2000)Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26:300-306
21. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E (2001) Loss of huntingtinmediated BDNF gene transcription in Huntington's disease. Science 293:493-498
22. Puttaraju M, Jamison SF, Mansfield SG, Garcia-Blanco MA, Mitchell LG (1999) Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat Biotechnol 17:246-252
23. Mansfield SG, Kole J, Puttaraju M, Yang CC, Garcia-Blanco MA, Cohn JA, Mitchell LG (2000)Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. Gene Ther 7:1885-1895
24. Kikumori T, Cote GJ, Gagel RF (2001) Promiscuity of premRNA spliceosome-mediated trans splicing: a problem for gene therapy? Hum Gene Ther 12:1429-1441
25. Puttaraju M, DiPasquale J, Baker CC, Mitchell LG, Garcia-Blanco MA (2001) Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA trans-splicing. Mol Ther 4:105-114
26. Labrador M, Corces VG (2003) Extensive exon reshuffling over evolutionary time coupled to trans-splicing in Drosophila. Genome Res 13:2220-2228
27. Flouriot G, Brand H, Seraphin B, Gannon F (2002) Natural transspliced mRNAs are generated from the human estrogen receptoralpha (hER alpha) gene. J Biol Chem 277:26244-26251
28. Dorn R, Krauss V (2003) The modifier of mdg4 locus in Drosophila: functional complexity is resolved by trans splicing. Genetica 117:165-177
29. Finta C, Zaphiropoulos PG (2002) Intergenic mRNA molecules resulting from trans-splicing. J Biol Chem 277:5882-5890
30. Caudevilla C, Serra D, Miliar A, Codony C, Asins G, Bach M, Hegardt FG (1998) Natural trans-splicing in carnitine octanoyltransferase pre-mRNAs in rat liver. Proc Natl Acad Sci USA 95:12185-12190
31. Bruzik JP, Maniatis T (1992) Spliced leader RNAs from lower eukaryotes are trans-spliced in mammalian cells. Nature 360: 692-695
32. Li H, Wang J, Mor G, Sklar J (2008) A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science 321:1357-1361
33. Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA (2009)SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 69:2734-2738
34. Coady TH, Baughan TD, Shababi M, Passini MA, Lorson CL (2008) Development of a single vector system that enhances trans-splicing of SMN2 transcripts. PLoS One 3:e3468
35. Gropp M, Itsykson P, Singer O, Ben-Hur T, Reinhartz E, Galun E, Reubinoff BE (2003) Stable genetic modification of human embryonic stem cells by lentiviral vectors. Mol Ther 7:281-287
36. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, Manoharan M, Sah DW, Zamore PD, Aronin N (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 104:17204-17209
37. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ, Davidson BL (2008) Artificial miRNAs mitigate shRNAmediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105:5868-5873
38. Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S, Bonvento G, Brouillet E, Luthi-Carter R, Hantraye P, Deglon N (2009)Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65:276-285
39. Mochizuki H, Yasuda T, Mouradian MM (2008) Advances in gene therapy for movement disorders. Neurotherapeutics 5: 260-269
40. Danos O (2008) AAV vectors for RNA-based modulation of gene expression. Gene Ther 15:864-869
41. Harper SQ (2009)Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol 66:933-938
42. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12:1555-1567
43. Wood M, Yin H, McClorey G (2007) Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 3:e109
44. Boado RJ, Kazantsev A, Apostol BL, Thompson LM, Pardridge WM (2000)Antisense-mediated down-regulation of the human huntingtin gene. J Pharmacol Exp Ther 295:239-243
45. Nellemann C, Abell K, Norremolle A, Lokkegaard T, Naver B, Ropke C, Rygaard J, Sorensen SA, Hasholt L (2000)Inhibition of Huntington synthesis by antisense oligodeoxynucleotides. Mol Cell Neurosci 16:313-323
46. Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, Wu J, Bezprozvanny I, Corey DR (2009)Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 27:478-484
47. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL (2009)Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17:1053-1063
48. White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, MacDonald ME (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17:404-410
49. Dietrich P, Shanmugasundaram R, Shuyu E, Dragatsis I (2009)Congenital hydrocephalus associated with abnormal subcommissural organ in mice lacking huntingtin in Wnt1 cell lineages. Hum Mol Genet 18:142-150
50. van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, Kaemmerer WF (2008) Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther 19:710-719
51. Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J, Linsley PS, Aronin N, Xu Z, Zamore PD (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2:e140
52. Zhang Y, Engelman J, Friedlander RM (2009)Allele-specific silencing of mutant Huntington's disease gene. J Neurochem 108:82-90
53. Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M, Landwehrmeyer B, Vonsattel JP, Zamore PD, Aronin N (2009)Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 19:774-778
54. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR (2009)Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 40:121-127
55. Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR (2011) Potent and selective antisense oligonucleotides targeting singlenucleotide polymorphisms in the Huntington disease gene/allelespecific silencing of mutant huntingtin. Mol Ther 19:2178-2185
56. McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, Davidson BL (2011) Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther 19:2152-2162
57. Lee SJ, Lim HS, Masliah E, Lee HJ (2011) Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res 70:339-348
58. Jucker M, Walker LC (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70:532-540
59. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR (2009)Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 11:219-225
60. Mitchell LG, McGarrity GJ (2005)Gene therapy progress and prospects: reprogramming gene expression by trans-splicing. Gene Ther 12:1477-1485
61. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A (2009)Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 219:385-397
62. Morris DP, Greenleaf AL (2000)The splicing factor, Prp40, binds the phosphorylated carboxyl-terminal domain of RNA polymerase II. J Biol Chem 275:39935-39943
63. Goldstrohm AC, Albrecht TR, Sune C, Bedford MT, Garcia-Blanco MA (2001) The transcription elongation factor CA150 interacts with RNA polymerase II and the pre-mRNA splicing factor SF1. Mol Cell Biol 21:7617-7628
64. Liu X, Jiang Q, Mansfield SG, Puttaraju M, Zhang Y, Zhou W, Cohn JA, Garcia-Blanco MA, Mitchell LG, Engelhardt JF (2002) Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol 20:47-52
65. Liu X, Luo M, Zhang LN, Yan Z, Zak R, Ding W, Mansfield SG, Mitchell LG, Engelhardt JF (2005)Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum Gene Ther 16:1116-1123
66. Chao H, Mansfield SG, Bartel RC, Hiriyanna S, Mitchell LG, Garcia-Blanco MA, Walsh CE (2003) Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med 9:1015-1019
67. Nakayama K, Pergolizzi RG, Crystal RG (2005)Gene transfermediated pre-mRNA segmental trans-splicing as a strategy to deliver intracellular toxins for cancer therapy. Cancer Res 65:254-263
68. Pergolizzi RG, Ropper AE, Dragos R, Reid AC, Nakayama K, Tan Y, Ehteshami JR, Coleman SH, Silver RB, Hackett NR, Menez A, Crystal RG (2003) In vivo trans-splicing of 50 and 30 segments of pre-mRNA directed by corresponding DNA sequences delivered by gene transfer. Mol Ther 8:999-1008
69. Tahara M, Pergolizzi RG, Kobayashi H, Krause A, Luettich K, Lesser ML, Crystal RG (2004)Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat Med 10:835-841
70. Wally V, Klausegger A, Koller U, Lochmuller H, Krause S, Wiche G, Mitchell LG, Hintner H, Bauer JW (2008) 50 transsplicing repair of the PLEC1 gene. J Invest Dermatol 128: 568-574